atg4b

Atg4B-IN-2. A potent, selective Atg4B inhibitor with anticancer activity, inhibits both Atg4B and PLA2, enabling autophagy that counteracts the anticancer activity of anti-desiccation-resistant prostate cancer drugs.

FMK 9a is an irreversible inhibitor of ATG4B with IC50 values of 80 and 73 nM in the TR-FRET and cellular-based LRA assays.

LV-320 is a potent, uncompetitive ATG4B inhibitor with an IC50 of 24.5 μM and a Kd of 16 μM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic, and active in vivo. These findings suggest that LV-320 will serve as a relevant chemical tool to study the various roles of ATG4B in cancer and other contexts [1].

S130 is a high affinity, selectiveATG4B (a major cysteine protease) inhibitor (IC50 of 3.24 μM).It suppresses autophagy flux.

RNF5 agonist 1 (analog-1), a structural analog of the RNF5 inhibitor inh-02, is a potent RNF5 agonist. In CFBE41o- cells expressing F508del-CFTR, RNF5 agonist 1 enhances the ubiquitination of ATG4B.

RNF5 inhibitor inh-02 is a selective inhibitor of the ubiquitin ligase RNF5/RMA1, which can significantly rescue F508del-CFTR (cystic fibrosis transmembrane conductance regulator with a deletion at position 508 of phenylalanine) and regulate ATG4B and paxillin, making it useful for studying cystic fibrosis (CF).

NSC 185058, an inhibitor of ATG4B (a major cysteine protease), can also attenuate autophagic activity.

STK683963 is a potent activator of ATG4B cellular activity and serves as a mediator for the redox regulation of ATG4B in cells. This compound is utilized in cancer research.

MJO445 (Compound 7) is an ATG4B inhibitor that suppresses glioblastoma autophagy [1].